Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), recently announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD).